Dr. Reddy’s Tightens Insider-Information Disclosure Code After Board Approval

Dr Reddy’s Laboratories ( (RDY) ) has shared an update.

On March 24, 2026, Dr. Reddy’s Laboratories’ board approved an amended Code of Practices and Procedures for Fair Disclosures of Unpublished Price Sensitive Information, aligning its internal framework with India’s SEBI insider trading and listing regulations. The updated code formalizes roles such as the Chief Investor Relations Officer, reinforces uniform and timely market disclosure, restricts selective and social media sharing of sensitive information, and mandates structured digital record-keeping and controls over legitimate access, signalling a tighter compliance posture for investors and regulators.

The company committed to promptly disseminating any inadvertent leaks of unpublished price-sensitive information, including within 24 hours of discovery, and to documenting investor interactions via website postings where required. The board also instituted detailed rules for sharing sensitive information for legitimate business purposes and for maintaining an eight-year digital database of who shares and receives such data, underscoring an operational focus on transparency, governance and mitigation of insider trading risks.

The most recent analyst rating on (RDY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.

Spark’s Take on RDY Stock

According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.

The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.

To see Spark’s full report on RDY stock, click here.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories is an India-based global pharmaceutical company engaged in the development, manufacture and marketing of generics, branded formulations and active pharmaceutical ingredients. Its shares are listed in India on the NSE and BSE and in the U.S. on the New York Stock Exchange, giving it a broad base of international investors and regulatory oversight.

Average Trading Volume: 1,926,712

Technical Sentiment Signal: Hold

Current Market Cap: $11.17B

For an in-depth examination of RDY stock, go to TipRanks’ Overview page.